Analysis of the Safety Profile of Direct Oral Anticoagulants Using the FDA Adverse Event Reporting System

被引：0
|
作者：
Deloughery, Emma P. [1 ]
Shatzel, Joseph J. [2 ]
机构：
[1] Mayo Clin, Sch Med, Rochester, MN USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-109818
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2531
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system
    DeLoughery, Emma P.
    Shatzel, Joseph J.
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (01) : 43 - 46
  • [2] Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
    Yibei Zhao
    Huiming Jiang
    Lifen Xue
    Mi Zhou
    Xiaobing Zhao
    Fei Liu
    SongJiang Jiang
    Jing Huang
    Long Meng
    [J]. International Journal of Clinical Pharmacy, 2024, 46 : 480 - 487
  • [3] Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
    Zhao, Yibei
    Jiang, Huiming
    Xue, Lifen
    Zhou, Mi
    Zhao, Xiaobing
    Liu, Fei
    Jiang, Songjiang
    Huang, Jing
    Meng, Long
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (02) : 480 - 487
  • [4] Analysis of the Safety Profile of Commonly Used Procoagulants Using the FDA Adverse Event Reporting System
    Deloughery, Emma P.
    Shatzel, Joseph J.
    [J]. BLOOD, 2018, 132
  • [5] STROKE AND THROMBOTIC EVENT ASSOCIATED WITH CONCOMITANT DIRECT ORAL ANTICOAGULANTS AND ANTIEPILEPTIC DRUGS IN THE FDA ADVERSE EVENT REPORTING SYSTEM
    Sunaga, T.
    Brown, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S98 - S99
  • [6] Discontinuation of Direct Oral Anticoagulants in Response to Attorney Advertisements: Data From the FDA Adverse Event Reporting System
    Mohamoud, Mohamed
    Patanavanich, Saharat
    Crew, Page
    McCulley, Lynda
    Munoz, Monica
    Kortepeter, Cindy
    Jones, S. Christopher
    Woronow, Daniel
    Dal Pan, Gerald
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (09) : 962 - 963
  • [7] A real-world analysis of safety profile of selexipag by using FDA adverse Event Reporting System (FAERS)
    Zhao, Jie
    Wang, Mei
    Yu, Qing
    Yang, Yi
    Zhang, Bin
    Zhan, Sanhua
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (07) : 937 - 948
  • [8] Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database
    Papazisis, G.
    Siafis, S.
    Cepatyte, D.
    Giannis, D.
    Stamoula, E.
    Tzachanis, D.
    Egberts, T.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (19) : 6003 - 6012
  • [9] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Zhang, Meilian
    Xie, Wenhuo
    Li, Jianbin
    Zheng, Jiaping
    Zhou, Yu
    [J]. ARCHIVES OF WOMENS MENTAL HEALTH, 2023, 27 (1) : 35 - 44
  • [10] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Meilian Zhang
    Wenhuo Xie
    Jianbin Li
    Jiaping Zheng
    Yu Zhou
    [J]. Archives of Women's Mental Health, 2024, 27 : 35 - 44
12345